Exubera lung-cancer risk found, Nektar Therapeutics ends partnership talks - San Francisco Business Times:

http://rouge.com/about-rouge.html
may be linked to lung cancer, the companies Pfizer, which stopped marketing the drug in October becaus ofpoor sales, said it updated Exubera's Meanwhile, Nektar (NASDAQ: NKTR), which had regained rightss to Exubera and was in negotiations with potential inhaled insulin partners, said it has broke off partnership talks as a result of Pfizer'ss findings. Six of 4,74o0 patients using Exubera developedlung cancer, according to a revieaw of clinical trial and data and other That's compared to one of 4,29q2 patients not using Exubera.
That's too few cases to determins whether the cancer is relatedto Exubera, the drug'sx updated label says, and all patients who were diagnosed with lung cancedr had a prior history of cigarettwe smoking. Yet the data is the latesg -- and possibly fatal -- blow to inhalex insulin. Pfizer's (NYSE: PFE) dropping of Exubera was followed by similar movesby LLY) and (NYSE: NVO), whicb had a inhaled insulin development with of Hayward. "Fortunately, over the past year Nektar has significantlyh transformedits business, moving away from inhaled insulin," said Nektar President and CEO Howarf Robin. Nektar, which agreed to pay past Exuberaspartners Inc. and up to $38.
e4 million for costs and expenses, will not incu any additional charged related to the lungcancefr warning, the company said.